NeuroVive Pharmaceutical AB Price/Book
Cos'è Price/Book di NeuroVive Pharmaceutical AB?
Price/Book di NeuroVive Pharmaceutical AB è 4.40
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su OTC rispetto a NeuroVive Pharmaceutical AB
Cosa fa NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Aziende con price/book simili a NeuroVive Pharmaceutical AB
- Lindian Resources ha Price/Book di 4.40
- Palantir Technologies ha Price/Book di 4.40
- Argent Minerals ha Price/Book di 4.40
- Nederlandsche Apparatenfabriek NV ha Price/Book di 4.40
- Msl Soltns Fpo ha Price/Book di 4.40
- Royal Nickel ha Price/Book di 4.40
- NeuroVive Pharmaceutical AB ha Price/Book di 4.40
- Novartis AG ha Price/Book di 4.40
- Polaris Inc ha Price/Book di 4.40
- Arman Services ha Price/Book di 4.41
- Aris Gold ha Price/Book di 4.41
- Subros ha Price/Book di 4.41
- HiTechPros SA ha Price/Book di 4.41